Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Gains Dx Commercialization Rights Under Modified Deal with bioMerieux

NEW YORK (GenomeWeb News) - ExonHit Therapeutics said today that it has amended its longstanding partnership with bioMerieux in order to gain commercial rights to cancer diagnostic kits developed through the agreement.
 
The amended agreement also gives bioMerieux “greater flexibility to initiate new research and development projects in that field,” ExonHit said.
 
The partnership began in 2003 to develop breast cancer diagnostics and was expanded in 2005 to include other types of cancers, including colon, prostate, and lung.
 
The goal of the partnership is to develop DNA microarrays to detect cancer markers in blood samples. ExonHit is providing its gene expression analysis know-how and intellectual property, and on bioMerieux is contributing its knowledge of in vitro diagnostics.
 
The companies are currently working on three programs: breast cancer, colorectal cancer, and prostate cancer.
 
Terms of the previous agreement gave bioMérieux an exclusive license to ExonHit’s technology and methods in the field of blood diagnostics, gene profiling, and microarray design. In exchange, bioMérieux covered ExonHit's R&D costs and provided milestone payments.
 
The new agreement will allow ExonHit to market the diagnostic kits developed through the partnership to pharmaceutical companies or to hospitals taking part in clinical studies, “in order to help them recruit patients for their clinical studies.”
 
Bruno Tocque, chairman of ExonHit’s management board, called the amendment “a major step forward in ExonHit's development because it allows us to consider generating our own source of revenues from products based on our technology which are issued from the collaboration."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.